Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis
Rubinstein S, Lynch R, Desai A, Stratton C, Jha A, Bakouny Z, Schmidt A, Sica R, Bhutani D, Shah D, Wall S, Lyman G, Kuderer N, Weiss M, Warner J, Stockerl-Goldstein K, Mesa R, Thompson M. Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. Blood 2020, 136: 28-30. PMCID: PMC8330211, DOI: 10.1182/blood-2020-141937.Peer-Reviewed Original ResearchSevere COVID-19COVID-19 outcomesSevere COVID-19 outcomesCOVID-19 diagnosisHematologic malignanciesCOVID-19 treatmentNational Cancer InstituteBristol-Myers SquibbPerformance statusClinical outcomesSupplemental oxygenICU levelMechanical ventilationPoor outcomeCytotoxic therapyCOVID-19Cancer InstituteEastern Cooperative Oncology Group performance statusLaboratory-confirmed COVID-19Cellular therapySars-Cov-2 infectionSevere COVID-19 illnessCytotoxic systemic therapyTherapy-related immunosuppressionPoor performance status